Healthcare
Pyxis Oncology, Inc.(PYXS)
Live Price
Offline$1.76
+5.39% today
1Y Change
+44.63%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $110.00M
- Revenue Growth
- -14.2%
- EPS Growth
- +3.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pyxis Oncology, Inc. (PYXS) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $1.76 and up 44.6% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -14.2%, EPS growth of +3.0%, a dividend yield of 0.0%. What stands out right now is revenue -14.2%, EPS +3.0%, free cash flow -9.7% with operating margin -609.2% and ROIC -117.1%. Valuation sits in the middle of the pack at price/sales 7.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PYXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.2% vs +7.6% peer median
Operating Margin
Below sector median
-609.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 14, 2026 with an EPS surprise of -5.7%.
The operating picture looks softer than before
Revenue is at -14.2% and EPS is at +3.0%, with operating margin around -609.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | -5.7% | +3.2% | -12.2% | -20.4% |
2026 Mar 23, 2026 | +17.1% | -4.2% | -10.6% | +20.4% |
2025 Nov 3, 2025 | +2.8% | +2.4% | +25.2% | +2.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYXS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PYXS Max Drawdown
-80.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PYXS and SPY.
Company Overview
Pyxis Oncology, Inc.
NASDAQ Global Select
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Thomas Civik
- IPO Date
- Oct 8, 2021
- Employees
- 44
- Street Address
- 35 Cambridgepark Drive
- Mailing
- Boston, MA, 02140
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 221 9059
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.8
- Price/Book
- 2.0
Growth
- Revenue
- -14.2%
- EPS
- +3.0%
- Free Cash Flow
- -9.7%
Profitability
- Gross Margin
- 103.1%
- Operating Margin
- -609.2%
- Net Margin
- -574.5%
- ROE
- -101.8%
- ROIC
- -117.1%
Balance Sheet
- Debt/Equity
- 0.35
- Current Ratio
- 3.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.